Profile data is unavailable for this security.
About the company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
- Revenue in HKD (TTM)5.80bn
- Net income in HKD586.56m
- Incorporated2010
- Employees3.64k
- LocationShanghai Henlius Biotech Inc11/F, B8 Building, No. 188 Yizhou Road,SHANGHAI 200233ChinaCHN
- Fax+86 2 134611802
- Websitehttps://www.henlius.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 7.48bn | 798.00 | 13.83 | 1.93 | 11.11 | 4.90 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Cansino Biologics Inc | 370.81m | -1.59bn | 7.51bn | 1.49k | -- | 0.8624 | -- | 20.26 | -6.45 | -6.45 | 1.50 | 22.94 | 0.0332 | 2.37 | 0.4619 | 248,201.00 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.76bn | 2.14bn | 7.88bn | 4.62k | 3.68 | 0.9249 | 3.27 | 1.17 | 2.43 | 2.43 | 7.68 | 9.69 | 0.5111 | 3.62 | 4.09 | 1,464,263.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| AIM Vaccine Co Ltd | 1.28bn | -1.40bn | 8.26bn | 1.62k | -- | 2.11 | -- | 6.47 | -1.15 | -1.15 | 1.05 | 3.23 | -- | -- | -- | 785,492.10 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Luye Pharma Group Ltd | 6.60bn | 572.15m | 10.61bn | 5.27k | 18.45 | 0.788 | 7.96 | 1.61 | 0.1529 | 0.1529 | 1.77 | 3.58 | 0.247 | 2.42 | 3.60 | 1,252,222.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.39bn | 1.21bn | 11.80bn | 1.05k | 10.11 | 3.22 | 8.67 | 3.48 | 1.85 | 1.85 | 5.21 | 5.81 | 0.7585 | 3.56 | 3.83 | 3,228,498.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
| Shanghai Henlius Biotech Inc | 5.80bn | 586.56m | 12.42bn | 3.64k | 21.23 | 5.27 | 12.77 | 2.14 | 1.08 | 1.08 | 10.62 | 4.33 | 0.5731 | 1.95 | 9.10 | 1,593,481.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 12.65bn | 5.60k | 9.62 | 1.82 | 7.23 | 1.96 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Zai Lab Ltd | 2.27bn | -2.65bn | 13.17bn | 2.18k | -- | 2.16 | -- | 5.79 | -2.73 | -2.73 | 2.35 | 6.12 | 0.2697 | 2.84 | 5.61 | -- | -31.41 | -37.72 | -36.81 | -42.72 | 62.86 | 64.75 | -116.45 | -282.44 | 4.43 | -- | 0.0596 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| Simcere Pharmaceutical Group Ltd | 7.10bn | 767.83m | 14.07bn | 7.03k | 19.20 | 1.86 | 12.79 | 1.98 | 0.288 | 0.288 | 2.72 | 2.97 | 0.6106 | 3.53 | 2.65 | 1,010,167.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 14.76bn | 2.90bn | 15.06bn | 15.00k | 5.19 | 1.10 | 4.29 | 1.02 | 1.60 | 1.60 | 8.12 | 7.53 | 0.6871 | 3.36 | 6.15 | 984,005.60 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| 3SBio Inc | 8.40bn | 1.66bn | 15.19bn | 5.41k | 9.45 | 1.01 | 7.36 | 1.81 | 0.6708 | 0.6708 | 3.44 | 6.29 | 0.3426 | 1.58 | 7.01 | 1,551,706.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 22.72 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| China Medical System Holdings Ltd | 8.61bn | 2.58bn | 15.98bn | 5.70k | 6.23 | 0.9633 | 5.69 | 1.86 | 1.05 | 1.05 | 3.51 | 6.80 | 0.4517 | 3.42 | 6.19 | 1,509,960.00 | 13.44 | 18.44 | 15.70 | 21.14 | 76.24 | 75.47 | 29.76 | 34.26 | 3.98 | -- | 0.0772 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 16.79bn | 10.53k | 8.83 | 1.09 | 7.34 | 1.59 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Data as of Jul 05 2024. Currency figures normalised to Shanghai Henlius Biotech Inc's reporting currency: Hong Kong Dollar HKD
1.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Qatar Investment Authority (Investment Management)as of 09 May 2024 | 1.68m | 1.03% |
| SSgA Funds Management, Inc.as of 06 Jun 2024 | 152.90k | 0.09% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 131.40k | 0.08% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 127.90k | 0.08% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 90.00k | 0.06% |
| DFA Australia Ltd.as of 31 May 2024 | 12.13k | 0.01% |
| Mackenzie Investments Corp. (United States)as of 29 Feb 2024 | 6.93k | 0.00% |
| Mackenzie Financial Corp.as of 30 Sep 2023 | 3.96k | 0.00% |
More ▼
Data from 31 Dec 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
